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Abstract
The incidence of NPC in Yogyakarta province is 6.2/100 000 population and the
tendency is increasing in the younger population. It has been known that drugs
resistance also issues in NPC therapy. Cisplatin is drugs of choice that used in NPC
therapy, besides miR-141 and mRNA PTEN are also had a role in chemotherapy
resistance in some of cancer. We conducted the examination of the expression of
miR-141 from blood plasma pre and post-therapy patient and blood plasma in healthy
control. The sample collected from whole blood and then plasma separation. RNA
extracted using RNA Isolation Kit miRCURY-Biofluid, synthesis cDNA with cDNA
Synthesis kit. mRNA analysis with KAPA SYBR® FAST One-Step qRT-PCR Kit then
detected by qRT-PCR. Data analysis with comparative analysis and statistical analysis.
MiR-141 showed upregulation by 1.49 (p-value: 0.075) and mRNA PTEN showed down-
regulation by 0.65 (p-value: 0.323) in patients NPC compared to healthy control and
there is a relationship between miR-141 and mRNA PTEN (p-value:0.001). The expression
levels of miR-141 in patients pre- and post-therapy experience down-regulated (fold
change:0.61, two-tailed t-test: 0.09) and mRNA expression levels of PTEN experience
down-regulated (fold change:0.5, t-test two-tailed:0.09). The level expression of
mRNA PTEN is still down-regulated through the expression of miR-141 is up-regulated
indicated that the possibility of drugs resistance in therapy with cisplatin. Then, miR-141
is one of the important factors in cisplatin drugs resistancewith inhibition of mRNAPTEN.
Keywords: miR-141, mRNA PTEN, Cisplatin, Drugs resistance, NPC.
1. Introduction
NPC is happening by insertion of EBV-DNA viruses. EBV infects B lymphocyte by
expressed the LMP1 (oncogene) to increase B-cell proliferation by making a similar
signal to activated B-cell by upper cell molecule B-cell, CD40. In another hand, LMP-1
is prevented apoptosis by activated BCL2. Then, the proliferation will be uncontrolled
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[1]. To achieve long-term in vivo, the EBV express the latent gene which causes latent
infection [2].
The drugs of choice in NPC therapy was cisplatin, an inorganic metal drugs as an
alkylating agent. As an alkylating agent, it works by inhibiting cross-linking in the N7
alkyl group of guanines and makes uncoil strand [3]. The issue of drugs resistance in
cancer therapy have been investigated after cisplatin therapy [4]. Molecular mechanism
of cisplatin resistance has been investigated caused by a kinase, such as Akt and YAP1.
Alteration of the kinase expressions has been influenced by the expression of a tumor
suppressor gene. MicroRNA, the single-strand non-coding RNA has been worked in
post-transcriptional mechanism and could be suppressed the expression of tumor sup-
pressor gene [5].
miR-141 have been investigated in NPC proliferation cells by downregulated PTEN, a
tumor suppressor gene as an antagonist in the AKT/PI3K pathway [6]. miR-141 have been
investigated a role in resistance to cisplatin in esophageal squamous cell carcinoma
by targeting YAP1 [7]. In ovarian cancer have been investigated the role of miR-141 in
cisplatin resistance by targeting KEAP1 [8]. Induction of NPC in Akt/FoxO pathway is
known to lead to their resistance to cisplatin [9].
A research study in NPC cells has investigated the role of miR-141 and mRNA PTEN
in NPC pathogenesis. miR-141 has been investigated as oncomiR and mRNA PTEN was
targetted [6]. In order to support the noninvasive biomarker agent in drugs resistance,
research onmiR-141 andmRNAPTEN expressionwas conducted in blood plasma of NPC
patients. At the same time, inhibition of EBV-miR to mRNA PTEN also done to investigate
the miRNA-miRNA interaction by in silico study.
2. Materials and Methods
2.1. Sample collections
Sample collections used was some blood patients with NPC (pre and post therapy)
and plasma of normal people from Dharmais Cancer Hospital and diagnoses of NPC
has been done by Cita Herawati. All sample experiments were approved by the ethical
committee of Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.
2.2. Material
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2.2.1. Equipment
Micropipet tube, microRNA mini spin column BF (Exiqon), vortex, centrifuge, spin down,
thermal cyder Biorad c1000, qRT-PCR Biorad.
2.2.2. Material
Alcohol 70%, isopropanol p.a, rDNAse,miRCURYRNA isolation kit- Biofluid Exiqon (Lysis
solution BF, Protein precipitation solution BF, Wash solution 1 dan 2 BF, RNAse free
water), kit universal cDNA synthesis kit II, 8-64 rxns (cat no. 2-33-1, exiqon), 5 times of
reaction buffer, nuclease free water, spike in (Sp6), enzyme mix, ice pack. miRCURY LNA
Universal RT micro RNA PCR, LNA PCR Primer Set, hsa-miR-141-3p UAACACUGUCUG-
GUAAAGAUG
For mRNA: KAPA SYBR® FAST One-Step qRT-PCR Kit Universal (KAPA SYBR FAST
qPCR master mix, ROX Reference Dye High, ROX Reference Dye Low, dUTP, KAPA
RT mix), primer set mRNA PTEN (forward: GGGTCTGAGTCGCCTGTCA, reverse: CCGT-
GTTGGAGGCAGTAGAAG), primer beta-actin (forward: GGGAATTCAAAACTGGAACG-
GTGAAGG, reserve: GGAAGCTTATCAAAGTCCTCGGCCACA). The primer of mRNA
PTEN was available from Vinciguerra, et al.[10].
2.3. Methods
2.3.1. Plasma isolation
Blood sample in vacutainer EDTA has been centrifuged at 1 500 rad · s−1 in 10 min and
collect the plasma. Total RNA from blood plasma was extracted using the miRCURY
RNA Isolation Kit-Biofluid (Cat No. 300112, Exiqon). Complementary DNA was prepared
from DNAse-treated RNA samples with Universal cDNA Synthesis kit II, 8-64 rxns (Cat.
No. 203301, Exiqon). Quantitative PCR was performed on a StepOnePlus real-time PCR
system (Applied Biosystems) using Exilent SYBR Green master mix (Cat No. 203402,
Exiqon). mRNA PTEN was detected using KAPA SYBR ®FAST One-Step qRT-PCR KIT
Universal, All instructions according to the manufacturer’s instructions.
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2.3.2. Quantitative real-time PCR
Total RNA from blood plasma was extracted using the miRCURY RNA Isolation Kit-
Biofluid (Cat No. 300112, Exiqon). Complementary DNA was prepared from DNAse-
treated RNA samples with Universal cDNA Synthesis kit II, 8-64 rxns (Cat. No. 203301,
Exiqon). Quantitative PCR was performed on a StepOnePlus real-time PCR system
(Applied Biosystems) using Excellent SYBR Green master mix (Cat No. 203402, Exiqon).
mRNA PTEN was detected using KAPA SYBR ®FAST One-Step qRT-PCR KIT Universal
2.3.3. Data analysis
Data have been analyzed with comparative quantitative, 2ΔΔCt method, using miR-16
and beta-actin Ct to reference gene.
3. Results
Table 1 describes the expression of miR-141 and mRNA PTEN in the sample. The expres-
sion of miR-141 has been upregulated after cisplatin therapy, but the expression of mRNA
PTEN have been downregulated after therapy. Its indicated that the therapy was not
responded.
Table 1: The expression of miR-141 and mRNA PTEN in blood plasma sample by Fold Change (2ΔΔCt
method).
Sample Before treatment After treatment
miR-141 1.49 0.61
mRNA PTEN 0.69 0.5
NPC happen because of EBV genome insertion. Then we conducted interaction
between EBV-miR with mRNA PTEN by in silico study with Vienna Package Software
(Figure 1). The study has been done for investigated the reason of down-regulated
of mRNA PTEN after therapy. All of EBV-miR have been targeted mRNA PTEN, which
means that its interaction may cause the down-regulated of mRNA PTEN.
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MFE Bart1-3p=–87.30 kcal · mol–1 MFE Bart1-5p=–86.50 kcal · mol–1 MFE Bart2-3p=–84.50 kcal · mol–1 MFE Bart2-5p=–87.30 kcal · mol–1 
    
MFE Bart3-3p=–85.80 kcal · mol–1 MFE Bart3-5p=–84.20 kcal · mol–1 MFE Bart4-3p=–84.40 kcal · mol–1 MFE Bart4-5p=–86.10 kcal · mol–1 
    
MFE Bart5-3p=–86.10 kcal · mol–1 MFE Bart5-5p=–89.40 kcal · mol–1 MFE Bart6-3p=–89.90 kcal · mol–1 MFE Bart6-5p=–86.60 kcal · mol–1 
   
MFE Bart7-3p=–85.80 kcal · mol–1 MFE Bart7-5p=–82.40 kcal · mol–1 MFE Bart8-3p=–87.70 kcal · mol–1 MFE Bart8-5p=–82.90 kcal · mol–1 
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MFE Bart11-3p=–85.80 kcal · mol–1 MFE Bart11-5p=–90.80 kcal · mol–1 MFE Bart12=–85.40 kcal · mol–1 MFE Bart13-3p=–86.50 kcal · mol–1 
    
MFE Bart13-5p=–82.90 kcal · mol–1 MFE Bart14-3p=–86.00 kcal · mol–1 MFE Bart14-5p=–86.30 kcal · mol–1 MFE Bart15=–84.50 kcal · mol–1 
 
    
MFE Bart16=–91.10 kcal · mol–1 MFE Bart17-3p=–87.00 kcal · mol–1 MFE Bart17-5p=–87.70 kcal · mol–1 MFE Bart18-3p=–86.00 kcal · mol–1 
4. Discussion
miR-141 have been investigated as oncomir by down-regulated mRNA PTEN in blood
plasma NPC. PTEN plays a role in conducting dephosphorylation of PIP3 into PIP2 on
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MFE Bart18-5p=–85.50 kcal · mol–1 MFE Bart19-3p=–85.80 kcal · mol–1 MFE Bart19-5p=–85.30 kcal · mol–1 MFE Bart20-3p=–87.60 kcal · mol–1 
    
MFE Bart20-5p=–87.10 kcal · mol–1 MFE Bhrf1-2-3p=–84.50 kcal · mol–1 MFE Bhrf1-2-5p=–85.10 kcal · mol–1 MFE Bhrf1-3=–89.00 kcal · mol–1 
Figure 1: mRNA PTEN-EBV-miR interaction by Vienna Package Software (Green: PTEN. Red: EBV-miR). The
strongest interaction was seen in PTEN-EBV-Bart10-5p (MFE=–95.90 kcal ⋅ mol–1).
Akt phosphorylation of PI3K pathway [9]. However, miR-141 as oncomir can inhibit the
expression of PTEN in post-transcriptional processes. The expression of oncomir also
decreased after drugs therapy, which it can increase the expression of mRNA target-
ted. However, the expression of mRNA PTEN was upregulated after therapy although
the expression of miR-141 was down-regulated. It has meant that the therapy was not
responded and there might be cisplatin resistance.
In cellular respond, cisplatin can be interacted with secondary thiols, like glutathione
and metallothionein. Glutathione-cisplatin conjugated exit from the cell by ATP-
dependent pump. After cisplatin interacted with DNA, it will inhibit proliferation by
activated DNA damage. Kinase such as Akt, PKC, and ERK is also involved in the
regulation of cell death that induced by cisplatin. miR-214 was promoted cisplatin
resistance by downregulating PTEN and Akt [11]. miR-141 might be promoted cisplatin
resistance by downregulating PTEN and Akt activated similar as miR-214.
The inhibition in mRNA PTEN by another oncomir, like EBV-miR, makes mRNA PTEN
down-regulated and not responded to cisplatin therapy. miRNA-miRNA interaction may
be potential on complex network regulation of biological processed [12]. Another miRNA
can influence any miRNA by regulated their targeted and modulated their activity [13].
DOI 10.18502/kls.v4i11.3853 Page 73
UASC Life Sciences 2016
5. Conclusions
miR-141 is one of the important factors in cisplatin drugs resistance through inhibition of
mRNA PTEN and Akt activated signaling. mRNA PTEN in NPC might be bound to EBV-
miR that makes mRNA PTEN down-regulated and not responded to cisplatin therapy
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